Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
insider bought yesterday too.. they seem to believe in what they have at these levels
you have a GREAT entry... i'd hold em
i have no position in it.. knew it looked great with the insiders buying but strapped for avail cash (have too many longs LOL)
g/l!
I saw that news, db7. I would normally take these profits from .59 but this company seems to have some very good things happening and might be a GREAT long term hold.
Lots of potential for an effective HIV treatment.
INO, Inovio Pharmaceuticals Synthetic DNA Vaccine Protects Against HIV in Non-Human PrimatesLast update: 7/5/2011 4:00:00 AMTwo scientific journals publish data showing robust, sustained T-cell responses and protection generated by Inovio's DNA vaccine BLUE BELL, Pa., July 5, 2011 /PRNewswire via COMTEX/ -- Inovio Pharmaceuticals, Inc. (INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that novel data from a preclinical study of its SynCon(TM) DNA vaccine against HIV were published in two separate scientific journals. In vaccinated animals, the studies demonstrated Inovio's HIV vaccine's ability to harness the power of the immune system, generating unique immune system responses, significant antigen-specific T-cell responses, and protection from the virus. The results were published in two peer-reviewed journals in papers co-authored by researchers from Inovio and its academic collaborators: Vaccine published a paper entitled "Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine"; PLoS One published the paper "Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccine." In the first study, the investigators generated a synthetic, optimized DNA vaccine encoding for a novel HIV envelope clade C protein utilizing Inovio's SynCon(TM) vaccine design process. Further optimization processes were conducted including codon/RNA optimization, and addition of a Kozak sequence and IgE leader sequence to enhance the expression of the vaccine in humans. Developing a vaccine for clade C is considered to be a very high priority since this clade or sub-type of HIV virus is most prevalent in many parts of Africa, India, and China. When assessed in rigorous tests, this vaccine construct generated robust and high levels of T cell responses that were up to three times greater than T cell responses from other comparable DNA vaccine constructs targeting HIV envelope. Two phase I human studies will test the immunogenicity of this vaccine in human volunteers in the U.S. and in Africa. In the second study, the investigators assessed the protective effects of Inovio's PENNVAX(TM) HIV DNA vaccines by examining an equivalent vaccine for the corresponding monkey virus, called SIV (simian immunodeficiency virus). The vaccine was encoded for the three major proteins (e.g. gag, pol, and env antigens) encoded within the retroviral genome and was delivered using Inovio's proprietary electroporation (EP) technology. Researchers evaluated the treatment using a novel gene microarray analysis along with standard immunological and flow-based activation assays. They observed several gene sequences that were differentially regulated in vaccine-protected groups compared to non-vaccinated animals. The novel microarray analysis used to test the vaccine effects of DNA vaccines demonstrated that Inovio's PENNVAX vaccination led to the increased production of several gene sequences, including those involved in interferon signaling as well as those involved in immune cell trafficking and cell cycle progression. These results are relevant to humans because understanding these mechanisms could provide better insight into the ways immune responses could protect PENNVAX-immunized individuals from infection and virus propagation and may aid in the further optimization of Inovio's HIV vaccine candidates currently in multiple Phase I clinical studies. Significantly, this study included a virus challenge in rhesus monkeys. Vaccinated animals were protected from a subsequent injection of the SIV (HIV-equivalent in non-human primates) virus (i.e. the vaccinated animals demonstrated strong control of viral replication and had significantly lower viral load) while also displaying significantly enhanced antigen-specific killer T cell responses, an outcome that Inovio has observed in multiple previous preclinical and clinical studies. By comparison, the non-vaccinated animals failed to control SIV virus infection. Generation of CD8+ killer T cells are considered instrumental in clearing cancerous or infected cells from the body and imperative to achieving sufficient potency of new vaccines against cancers and chronic infectious diseases such as HIV and hepatitis C. Dr. J. Joseph Kim, Inovio's president and CEO, said: "This new preclinical data further validates the ability of Inovio's vaccines to induce powerful antigen-specific immune responses. In the past year, we have demonstrated best-in-class clinical immunogenicity data from our DNA vaccines for cervical cancer and HIV in Phase I studies. Collectively, these clinical and preclinical studies further substantiate our product development efforts in these important disease areas." Late last year, Inovio announced interim immunogenicity and safety data in humans from its Phase I clinical study of PENNVAX(TM)-B, a DNA vaccine for the prevention of HIV clade B infection. PENNVAX-B achieved high vaccine-induced response rates and strong magnitude of T cell immune responses in vaccinated subjects. Similar to reported results from a Phase I clinical study of Inovio's therapeutic DNA vaccine for cervical cancer, the response rates and magnitude of responses achieved in this study were significantly higher than those seen previously from other DNA vaccine trials. The complete immunogenicity data and end-of-study safety data from PENNVAX-B study are expected in the third quarter of this year. In a separate study, PENNVAX-B is also being tested as a therapeutic vaccine in HIV-positive volunteers, with immunogenicity and safety data expected in the fourth quarter of 2011. Two Phase I studies will test the optimized clade C DNA vaccine reported in the Vaccine paper. One study involves Inovio's global HIV DNA vaccine candidate, PENNVAX(TM)-G (clades A, C, and D), which is currently being tested in a 92-patient global Phase I clinical study in the U.S. and Africa in a collaboration with the U.S. Military HIV Vaccine Research Program. Inovio plans to initiate another Phase I study in mid-2012 with its PENNVAX(TM)-GP vaccine (against HIV clades A and C; intradermal delivery), which is being developed using a multi-year $25-plus million NIAID development contract awarded to Inovio. About Inovio Pharmaceuticals, Inc. Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon(TM) vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio clinical programs include three Phase II studies for vaccines treating cervical dysplasia/cancer, hepatitis C virus, and leukemia. Other clinical programs target influenza (preventive) and HIV (preventive and therapeutic). Inovio partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at . This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended March 31, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. CONTACTS:Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.comMedia: Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com SOURCE Inovio Pharmaceuticals, Inc. Copyright (C) 2011 PR Newswire. All rights reserved
GLDN starting its bounce back from last week...
INO more insider buys filed fwiw
CYTL +15.79 on lite vol>
CYTL... very thin on the bounce back up
UTOG will bounce today having resumed trading today and striking oil yesterday!
yep.. i just marked him
Yep. Many thanks to sterlingkuning for bringing it up!
wow! nice and fast.. great trade
Out @2.73 eom
Sweet..Good bounce or even swing play as well imo
$4 target
Shipping has been pummeled... FREE has lowest market cap of them all (OCNF, DRYS, etc) and extremely low float
It does look enticing here. Watching it.
I am. All the way to zero.
DIAAF in at .0065 and .006 BOING!
those are garbage posts and if i saw them in time i would have deleted them..
glad you have time for research like that lol.. maybe better spend it on researching stock picks ;)
apologize for not being more specific and will work on updating it.. fwiw, i've seen you on some hot picks before and even have you member marked
fwiw, this board is moreless for > .50 and listed stocks
g/l!!
oh I see its for pinks like these, and others posted in the history, but not for mine... well then this board should either have a criteria disclaimer or be a premium board!!
delete my post for speaking out, and i will just petition ADMIN to recycle it..as your being discriminatory
#19324 VSHC !!! >>>> http://investorshub.advfn.com/boards/read_msg.aspx?message_ stockraker 04/12/11 06:53:11 PM
#19323 PURO > .002 - Down from .20 just figone 04/09/11 04:10:39 PM
oh sorry what is this board for?
You dont even have an intro message disclaiming anything!
this board is not for pinks like that..thanks and g/l
keep eye on DIAAF .0065
GFRE good numbers
NEOP Morgan Joseph Starts Neoprobe Corp. (NEOP) at Buy; Labeling The Lymphatic System With Lymphoseek
Morgan Joseph initiates coverage on Neoprobe Corp. (NYSE: NEOP) with a Buy. PT $9.
Morgan analyst say, "In our view, Lymphoseek could become the market leader in the intra-operative lymphatic mapping (ILM) space based on its clinical utility in breast cancer, melanoma, and head and neck cancer. The agent has demonstrated clear statistical superiority to the existing labeling approach, vital blue dye, in clinical trials. We expect Neoprobe to file for approval of Lymphoseek in the US in 3Q 2011."
For more ratings news on Neoprobe Corp. click here and for the rating history of Neoprobe Corp. click here.
Shares of Neoprobe Corp. closed at $4.66 yesterday, with a 52 week range of $1.50-$5.14.
NEOP: Neoprobe's Lymphoseek Met All Endpoints in the Phase III NEO3-09 Study- NDA Submission Expected 3Q11
Neoprobe's Lymphoseek Met All Endpoints in the Phase III NEO3-09 Study
-NDA Submission Expected in 3Q11-
Report is Available for Download at: www.lifesciadvisors.com/clients/neoprobe
ENCINITAS, Calif., May 5, 2011-On Tuesday May 3rd, 2011, after the market close, Neoprobe Corporation (NYSE Amex: NEOP) issued a press release announcing the positive top-line results from the Lymphoseek (tilmanocept) Phase III NEO3-09 study. The NEO3-09 study met all of its endpoints and it is the second successful Phase III study conducted by Neoprobe for Lymphoseek. With both of these successful Phase III programs completed that are required for a New Drug Application (NDA), we expect the Company to submit during 3Q11.
Lymphoseek Hits on All Fronts and Demonstrates Superiority over VBD. The NEO3-09 study enrolled over 150 patients with breast cancer or melanoma that were included in the intent-to-treat (ITT) population. The primary endpoint of the study was the concordance rate of Lymphoseek versus vital blue dye (VBD) in intraoperative lymphatic mapping (ILM). Meaning that the ability of Lymphoseek to detect lymph nodes with metastasis was directly compared with VBD, the “Truth Standard.” As shown in Figure 1 below, there were over 200 lymph nodes stained by VBD in NEO3-09 and Lymphoseek detected 100% of them (p<0.0001). On the other hand, when Lymphoseek was used as the Truth Standard for statistical analysis, the reverse concordance rate for vital blue dye was approximately 60%, demonstrating that VBD is in fact inferior to Lymphoseek in detecting lymph nodes. Ultimately, a pre-specified, prospective test of superiority showed that Lymphoseek performed statistically superior to VBD.
Also measured in the study, was the ability for Lymphoseek to detect lymph nodes that contained cancer. Neoprobe noted in the press release that the ILM procedures during NEO3-09 found pathology-confirmed, cancer-positive lymph nodes at a rate consistent with the general rate of nodal involvement usually observed in breast cancer and melanoma. Lymphoseek detected all of the pathology-confirmed, cancer-positive nodes, resulting in a failed detection rate of 0%, while VBD missed over a 1/4 of cancer positive nodes (Figure 1). Hence, Lymphoseek was more effective at identifying lymph nodes containing metastasis, which is the primary objective of ILM. On the whole, these study results were consistent with the findings from the earlier successful NEO3-05 study and investors should now view the program with less risk.
Excellent Safety Profile Demonstrated. To-date, there have been no clinically significant drug-related adverse events or serious adverse events reported in over 500 subjects and both completed Phase III studies (NEO3-05 and NEO3-09). Worth noting, several significant drug-related AEs were reported for VBD. A typical full regional lymph node dissection procedure removes 20-30 lymph nodes in breast cancer or melanoma patients and may cause complications such as lymphedema, seroma, and infection. In the less invasive procedure involving Lymphoseek, an average of 2.4 lymph nodes (Figure 1) per patient were removed, which should lead to lower complication rates. The efficacy data coupled with a great safety profile bodes well for investors and Neoprobe as the Company moves forward to NDA submission.
The full NEO3-09 data set will be presented at the 2011 Annual Meetings of the American Society of Clinical Oncology held June 3rd-7th in Chicago due to an embargo, and we expect that this data will be even more telling in regards to Lymphoseek’s ability to detect lymph nodes containing tumor metastasis. For additional background on the NEO3-05 and NEO3-09 studies, please view our Initiation Report at: http://www.lifesciadvisors.com/clients/neoprobe/.
Upcoming Expected Milestones
• 2Q11- Full data set from NEO3-09 Lymphoseek Phase III Trial presented at ASCO
• 1H11- Amend RIGScan EU Scientific Advice
• 3Q11- Submit NDA for Lymphoseek to FDA
• 2H11- FDA acceptance of NDA for Lymphoseek/ announce PDUFA date
• 2H11- Potential for interim data from NEO3-06 Lymphoseek Phase III Trial
• 2H11- Finalize RIGS protocol with FDA and EMA in the US and EU
• 2H11- Re-initiate RIGS manufacturing
• 1H12- FDA marketing clearance/ approval for Lymphoseek
• 1H12- Re-initiate human clinical studies of RIGScan
About the Company: Our Initiation of Coverage Report and more information on the Company, including the full version of this report can be found at www.lifesciadvisors.com.
Still plenty of time, sitting @ 4.42
It made a nice bounce of of 4.41. I've been watching it since you mentioned it, but haven't jumped in. That dip today would have been a good place to load-up IMO.
Neoprobe Corporation (NASDAQ:NEOP) was initiated with Outperform and a target price of $7 at JMP Securities
NEOP, I am still looking for $6.50-$7.50 or more.
Neoprobe Corp. could charge a lot more for a diagnostic helper used in cancer surgery – if it gets regulatory approval – because of study results indicating the drug is superior to existing alternatives.
The Dublin biotech company (AMEX:NEOP) said Tuesday it remains on track for submitting in the third quarter its application to get approval to sell the drug Lymphoseek from the U.S. Food and Drug Administration. Investors had been hoping for a June submission.
The delay, in part, was to finish the study whose results were announced Tuesday, indicating the drug is not only safer than the current alternative but works better.
If the FDA approves a “superiority” claim on the drug’s label, the price goes up.
Executives on a Wednesday conference call said they were working with the exclusive distributor, Dublin-based Cardinal Health Inc. (NYSE:CAH), to determine the market price. The company has estimated the potential market for the drug at $450 million, but did not say what the higher price would do to that estimate.
Before his retirement, former CEO David Bupp in March had told analysts the company could justify a per-dose price of about $400 because it would replace a two-drug combo that costs that much. The two drugs are being used for a purpose not listed in their FDA labels.
If approved, Lymphoseek would be the only drug given the green light for use in an operation to seek about one to three lymph nodes that drain directly from the site of a breast or skin tumor so they can be tested for cancer’s spread.
The alternative is removing large clumps of 20 to 30 lymph nodes, which can lead to a lifetime of pain and swelling.
The FDA requires two phase III human trials before seeking sales approval. This second study reported no side effects from 500 patients receiving Lymphoseek, while some patients who received the blue dye currently used in the procedure reported adverse reactions.
More importantly, it performed better at finding the lymph nodes draining from the tumor. Lymphoseek detected 100 percent of those flagged by dye, but the dye found just 60 percent of those flagged by Lymphoseek.
When the nodes were biopsied, every one that turned out to contain cancer had been tagged by Lymphoseek while the dye missed 25 percent of the nodes with cancer.
“Lymphoseek provided clinically meaningful advantages over the blue dyes and I believe it will be a useful agent in (the lymph node mapping surgery),” said a statement from Dr. Vernon Sondak, skin cancer chief at Tampa, Fla., based Moffitt Cancer Center and Research Institute, one of the test sites.
Shares in Neoprobe hit a 52-week record high of $5.14 in Wednesday morning trading before leveling off. The low over the past year was $1.50 when it was still an over-the-counter stock. The company recently agreed to reshape its board at the suggestion of its largest investor.
NEOP @ 4.40. I still think there is plenty of room. Looking for around $6.50-$7.00. In @ 1.75
Out GHLV @ .0801 from .034. got my initial investment back. plus beer money. Still holding 14,000 shares. waiting for .10-.15
AIS insider buy just filed
Excellent call on FOH db7! Up 25% since you mentioned it!
AIS does look good around the 200 day
you are correct.. i'm slacking on catching the spammers
I don't think that pinksheets are appropriate for this board.
Nice call on DYAX...started to reverse last week.
Followers
|
80
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
19492
|
Created
|
01/23/04
|
Type
|
Free
|
Moderator VINOBBBY | |||
Assistants eagle_2975 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |